retatrutide clinic Retatrutide: A Promising Option for Non-Diabetic Weight Loss in Clinical Trials Retatrutide Results: 28.3% Weight Loss

This review also briefly assesses adjunctive therapies rooted in traditional Chinese medicine, including bioactive monomers, compound herbal formulas, and external treatment modalities

New real-world research presented at the AAAAI Annual Meeting suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may significantly reduce asthma exacerbations in overweight and obese adults without diabetes pointing to a potential new therapeutic strategy for a difficult-to-treat population.

GLP-1 receptor agonists may significantly reduce the risk for cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors, according to data presented at the EULAR 2025 Congress.“Our aim was to investigate whether GLP-1 receptor agonists could have a protective effect for the treatment of RA patients on JAK inhibitors to reduce cardiovascular

My takeaway Most obesity developers are pursuing either oral or injectable strategies

Both compounds suppressed caloric intake, promoted a marked weight loss, improved glucose tolerance and reduced plasma cholesterol levels

Zepbound is now available through RoenRx